Frontlight ResearchEarly access
WithdrawnNo phase
Verily Watch Cardio (AF and ECG) Study
Key facts
- Who runs it
- Verily Life Sciences LLC
- Where
- Lakewood, Southfield, and Winston-Salem, United StatesSee the 3 sites
- Trial code
- Status
- Withdrawn
- Started
- Nov 2023
- Ended
- Nov 2024
- Type of study
- Observational
- Treatments tested
- Verily Watch Cardio
- iRhythm Zio monitor
- Schiller CARDIOVIT FT-1
- Record updated
- 22 December 2023
- Why it stopped
- It was decided by Verily Leadership to not pursue the study any further.
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- At least 22 years old
- Able to read and speak English
- Participant understands the study requirements and is able and willing to sign written Informed Consent
- At risk of having an AF event, as determined by having a diagnosis of paroxysmal AF (PAF) and meeting one or more of the following:; Scheduled or to be scheduled to undergo AF ablation; AF burden of ≥25% in the 3 months prior to consent date as confirmed via an implantable loop recorder (ILR), holter monitor, or adhesive monitoring patch; CHA2DS2VASc score ≥3; Left atrial diameter ≥4.4 cm as confirmed by transthoracic echo (TTE) within one year of consent
- Without significant limitation in ability to participate in the study, in the opinion of the Investigator
Who cannot take part
- Currently on class Ic or class III antiarrhythmic medication that has been successful in eliminating AF (no documented AF of more than 30 seconds since the initiation of the medication). Should be at least one week off medication
- Known severe allergy to nickel or metal jewelry
- Known allergic reaction to polyester, nylon, spandex, adhesives or hydrogels; or with family history of adhesive skin allergies
- Have a pacemaker or implantable cardioverter defibrillator (ICD)
- Had successful AF ablation (no documented AF of more than 30 seconds post procedure)
- Are diagnosed with persistent AF
- Have an implantable neuro-stimulator
- Currently wearing an ECG patch that prevents the use of the FDA-cleared wearable ECG patch, at the discretion of the Investigator
- Have discolored wrists (e.g., tattoos, ink), at the discretion of the Investigator
Where in United States
- Colorado Heart and VascularLakewood, United States
- Ascension Providence HospitalSouthfield, United States
- Wake Forest Medical CenterWinston-Salem, United States
About the trial
What the trial wants to find out
This study is designed to evaluate the performance of the Verily Watch Cardio for recording electrocardiogram (ECG) and photoplethysmography (PPG) signals and detecting suspected atrial fibrillation (AF) episodes, in a free-living environment, in participants at risk for having an AF event.
The group in the trial
- Paroxysmal Atrial Fibrillation Patients
Treatment: Verily Watch Cardio, iRhythm Zio monitor, and Schiller CARDIOVIT FT-1
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 December 2023